Pulmonary arterial hypertension: current therapeutic strategies (Q36830717)

16 August 2017

1 reference

title

Pulmonary arterial hypertension: current therapeutic strategies (English)

1 reference

16 August 2017

arterial hypertension

1 reference

1

Aniket Puri

1 reference

16 August 2017

Michael D McGoon

2

1 reference

PubMed ID

17522721

16 August 2017

Sudhir S Kushwaha

series ordinal

3

1 reference

16 August 2017

1 June 2007

1 reference

Nature Clinical Practice Cardiovascular Medicine

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

6

1 reference

16 August 2017

319-329

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

Adenosine as a vasodilator in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

The right ventricle in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Primary pulmonary arterial hypertension: a look back

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Clinical classification of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Heterogeneity of pathologic lesions in familial primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein tùype II receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Transforming growth factor-betas and vascular disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The effect of amlodipine on exercise-induced pulmonary hypertension and right heart function in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Beraprost therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Endothelin system: the double-edged sword in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The endothelin system in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Sitaxsentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Sildenafil in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

PDGF signaling in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Unexplained pulmonary hypertension in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Reversal of experimental pulmonary hypertension by PDGF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Imatinib for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Long term imatinib treatment in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Simvastatin enhances bone morphogenetic protein receptor type II expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Interaction of KATP channels and endothelin-1 in lambs with persistent pulmonary hypertension of the newborn

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Primary pulmonary hypertension in pregnancy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Medical therapy of pulmonary hypertension. Conventional therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Transplantation as a treatment for end-stage pulmonary hypertension in childhood

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: Is more better?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0890

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0890

1 reference

16 August 2017

1 reference

PubMed ID

17522721